Masitinib: Difference between revisions
CSV import |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Masitinib''' is a [[tyrosine kinase inhibitor]], a type of [[drug]] used in the treatment of certain types of [[cancer]]. It is developed by [[AB Science]], a pharmaceutical company based in France. | '''Masitinib''' is a [[tyrosine kinase inhibitor]], a type of [[drug]] used in the treatment of certain types of [[cancer]]. It is developed by [[AB Science]], a pharmaceutical company based in France. | ||
[[File:Masitinib structure.svg|Masitinib|thumb]] | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Masitinib works by inhibiting the activity of certain [[protein]]s known as tyrosine kinases. These proteins play a key role in the signaling pathways that control cellular processes such as growth, division, and death. By blocking these proteins, masitinib can help to slow down or stop the growth of cancer cells. | Masitinib works by inhibiting the activity of certain [[protein]]s known as tyrosine kinases. These proteins play a key role in the signaling pathways that control cellular processes such as growth, division, and death. By blocking these proteins, masitinib can help to slow down or stop the growth of cancer cells. | ||
| Line 24: | Line 24: | ||
[[Category:Tyrosine kinase inhibitors]] | [[Category:Tyrosine kinase inhibitors]] | ||
{{Pharma-stub}} | {{Pharma-stub}} | ||
Latest revision as of 01:17, 6 March 2025
Masitinib is a tyrosine kinase inhibitor, a type of drug used in the treatment of certain types of cancer. It is developed by AB Science, a pharmaceutical company based in France.
Mechanism of Action[edit]
Masitinib works by inhibiting the activity of certain proteins known as tyrosine kinases. These proteins play a key role in the signaling pathways that control cellular processes such as growth, division, and death. By blocking these proteins, masitinib can help to slow down or stop the growth of cancer cells.
Uses[edit]
Masitinib is used in the treatment of certain types of cancer, including gastrointestinal stromal tumors (GISTs), mastocytosis, and some forms of lymphoma. It is also being investigated for use in other conditions, such as Alzheimer's disease, asthma, and multiple sclerosis.
Side Effects[edit]
Like all drugs, masitinib can cause side effects. These can include nausea, vomiting, diarrhea, and fatigue. In some cases, it can also cause more serious side effects, such as heart problems, liver damage, and skin reactions.
Development and Approval[edit]
Masitinib was developed by AB Science, a pharmaceutical company based in France. It has been approved for use in the European Union and several other countries. However, as of 2021, it has not yet been approved by the Food and Drug Administration (FDA) in the United States.
See Also[edit]
